- Home
- FBYD vs PROK Comparison
FBYD vs PROK Comparison
Compare FBYD & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBYD | PROK |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.3M | 316.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FBYD | PROK |
|---|---|---|
| Price | $7.41 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 119.9K | ★ 1.2M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $14,896,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $168.75 | ★ N/A |
| Revenue Growth | 120.85 | ★ 1075.00 |
| 52 Week Low | $3.71 | $1.30 |
| 52 Week High | $29.02 | $3.48 |
Technical Indicators
Market Signals| Indicator | FBYD | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 42.32 |
| Support Level | $5.80 | $1.56 |
| Resistance Level | $8.08 | $2.01 |
| Average True Range (ATR) | 0.75 | 0.12 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 52.85 | 9.71 |
Price Performance
Historical ComparisonAbout FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.